Analysis
Roughly a dozen companies filed S-1 or S-1/A registrations with the SEC on October 1 and 2, and the list is a useful reality check against the mega-deal IPO headlines Pulse has covered all year. The filers: BioStem Technologies, Georgia Banking Co, Vertical Data, Sunshine Biopharma, HCW Biologics, VSee Health, Youmi Inc, and T3 Defense among the operating companies, plus Arca Nova Acquisition Corp and Allarity Acquisition Corp -- both blank-check SPAC vehicles rather than businesses with existing operations.
That's a sharp contrast with the IPO pipeline's biggest names this year:
- SpaceX -- went public in June at roughly a $1.77T valuation under ticker SPCX, the largest IPO on record
- OpenAI -- reported IPO target near $1T
- Anthropic -- confidential filing reported to target roughly $2T
“None of this means the broader IPO market is dead -- a community bank or a biopharma filing an S-1 is routine, unglamorous market function, not a sign of distress.”
Those three companies alone likely represent more combined market value than every operating company that filed an S-1 this week, combined, many times over.
None of this means the broader IPO market is dead -- a community bank or a biopharma filing an S-1 is routine, unglamorous market function, not a sign of distress. What it does mean is that the "IPO window is open" narrative driven by AI megacaps doesn't describe the experience of a typical venture-backed company deciding whether to file. Pulse has flagged the SPAC-heavy tilt in recent filing batches before; this week's batch continues that pattern, with two of roughly a dozen new filings structured as blank checks rather than operating businesses.
For founders mapping their own IPO timeline, the microcap and SPAC filers are the more representative comp set than SpaceX or Anthropic -- however rare the trillion-dollar debuts, they are the exception the rest of the pipeline is being measured against unfairly. The running tally of both ends of that pipeline lives on Pulse's stats page.
